JMP Securities Maintains Market Outperform on Prime Medicine, Lowers Price Target to $6
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
JMP Securities analyst Silvan Tuerkcan maintains Prime Medicine (NASDAQ:PRME) with a Market Outperform and lowers the price target from $10 to $6.
JMP Securities analyst Silvan Tuerkcan maintains Prime Medicine (NASDAQ:PRME) with a Market Outperform and lowers the price target from $10 to $6.